Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hematological Malignancies”

276 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 276 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04205409
What this trial is testing

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more
University of Washington 20
Early research (Phase 1)Study completedNCT02543879
What this trial is testing

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplastic Syndrome+1 more
Forma Therapeutics, Inc. 94
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Early research (Phase 1)Study completedNCT00588991
What this trial is testing

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Who this might be right for
Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT04109482
What this trial is testing

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Mustang Bio 3
Early research (Phase 1)Study completedNCT00904787
What this trial is testing

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Relapsed or Refractory Hematological Malignancies
CASI Pharmaceuticals, Inc. 27
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Early research (Phase 1)Study completedNCT01300026
What this trial is testing

AMG 319 Lymphoid Malignancy FIH

Who this might be right for
CancerChronic Lymphocytic LeukemiaDiffuse Large Cell Lymphoma+11 more
Amgen 28
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07175415
What this trial is testing

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Princess Maxima Center for Pediatric Oncology
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Early research (Phase 1)Ended earlyNCT06343376
What this trial is testing

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+11 more
Roswell Park Cancer Institute 1
Very early researchUnknownNCT04011293
What this trial is testing

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Who this might be right for
Relapsed or Refractory Hematological Malignancies
Shandong University 20
Testing effectiveness (Phase 2)Study completedNCT00936117
What this trial is testing

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

Who this might be right for
LeukemiaFungal Infection
M.D. Anderson Cancer Center 25
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Very early researchLooking for participantsNCT04227015
What this trial is testing

CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 72
Testing effectiveness (Phase 2)Study completedNCT00027560
What this trial is testing

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+2 more
Memorial Sloan Kettering Cancer Center 51
Early research (Phase 1)Looking for participantsNCT07173595
What this trial is testing

A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd. 186
Load More Results
42